Table 1 Changes in anti-T. cruzi seroreactivity according to assay and treatment group
From: Assessing antibody decline after chemotherapy of early chronic Chagas disease patients
Antigen | Number positive/examined (%) by detection assay | |||||
|---|---|---|---|---|---|---|
Protein G: Chagas Sero K-SeT | IgG1 ELISA | IgG ELISA | ||||
TSSApep-II/V/VI | Lysate | TSSApep-II/V/VIa | Lysate | TSSApep-II/V/VIa | ||
Group A (n = 58) | ||||||
Positive (pre-treatment) | 54/58 (93.1%) | 46/58 (79.3%)f | 22/53b (41.5%)f | 57/58 (98.3%)g | 41/53b (77.4%)g | |
Clear decline | 25/54 (46.3%) | 35/46 (76.1%) | 22/22 (100%) | 21/57 (36.8%) | 34/41 (82.9%)e | |
Seronegativisation | 11/54 (20.4%) | 19/46 (41.3%)h | 15/22 (68.2%)i | 6/57 (10.5%)h | 18/41 (43.9%)i | |
Remained seronegativec | 4/58 (6.9%) | 12/58 (20.7%) | 30/53d (56.6%) | 1/58 (1.7%) | 12/53d (22.6%) | |
Group B (n = 13) | ||||||
Positive (pre-treatment) | 11/13 (84.6%) | 11/13 (84.6%) | 7/10b (70.0%) | 13/13 (100%) | 10/10b (100%) | |
Clear decline | 5/11 (45.5%) | 6/11 (54.5%) | 6/7 (85.7%) | 6/13 (46.2%) | 5/10 (50.0%)e | |
Seronegativisation | 1/11 (9.1%) | 2/11 (18.2%) | 5/7 (71.4%)j | 1/13 (7.7%) | 2/10 (20.0%)j | |
Remained seronegativec | 2/13 (15.4%) | 2/13 (15.4%) | 3/10 (30.0%) | 0/13 (0%) | 0/10 (0%) | |